Rapamycin fails to raise regulatory T-cell levels in RAP-ALS trial

How hope is everywhere when our community gathers

This past Sunday dawned crisp and cool on the eastern shore of Maryland, with a hint of light rain falling from a few clouds dappled against an otherwise vivid blue sky. I dressed to be outdoors, making sure my orange Tim Lowrey Panel T-shirt was visible under my jacket,…

Man with ALS controls devices using brain-computer interface

A man with amyotrophic lateral sclerosis (ALS) was able to control external devices — lighting and a TV — with only his thoughts using a brain-computer interface (BCI) device, according to a recent study. Called Cortical Communication (CortiCom), the BCI system learns to predict a person’s intended action by…

Zydus launches Phase 2 trial of anti-inflammatory ZYIL1

Zydus Lifesciences has launched a Phase 2 clinical trial to evaluate the safety and effectiveness of its experimental anti-inflammatory therapy ZYIL1 in people with amyotrophic lateral sclerosis (ALS). The company announced it has received clearance for the clinical trial (NCT05981040) from India’s Central Drugs Standard Control Organization…